Related Experiment Video

Updated: Mar 21, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.7K

Pharmacology and rationale for imatinib in the treatment of scleroderma

Pia Moinzadeh1, Nicolas Hunzelmann1, Thomas Krieg1

  • 1Department of Dermatology and Venerology, University of Cologne, Germany.

Journal of Experimental Pharmacology
|May 18, 2016
PubMed

Insights

Systemic sclerosis treatment remains challenging. Imatinib, a tyrosine kinase inhibitor, showed anti-inflammatory and antifibrotic effects in preclinical scleroderma models but failed to confirm these results in clinical trials.

Area of Science:

  • Immunology
  • Fibrosis Research
  • Pharmacology

Background:

  • Systemic sclerosis (scleroderma) is a chronic, multisystem, fibrotic disease with unclear pathogenesis.
  • Vascular damage initiates inflammation and fibrosis, with current therapies limited to managing organ complications.
  • Existing immunosuppressive and antifibrotic treatments lack significant breakthroughs.

Purpose of the Study:

  • To evaluate imatinib's potential as an antifibrotic therapy for systemic sclerosis.
  • To investigate imatinib's mechanism of action targeting TGF-β and PDGF signaling pathways.
  • To assess imatinib's efficacy based on preclinical and clinical evidence.

Main Methods:

  • Preclinical studies using mouse models of scleroderma.
  • Clinical, proof-of-concept trials in patients with systemic sclerosis.
  • Analysis of imatinib's effects on transforming growth factor-β and platelet-derived growth factor signaling.

Main Results:

  • Preclinical studies demonstrated significant anti-inflammatory and antifibrotic effects of imatinib.
  • Clinical trials did not confirm the promising results observed in preclinical models.
  • Imatinib interferes with key fibrotic signaling pathways.

Conclusions:

  • Imatinib exhibits preclinical anti-fibrotic and anti-inflammatory properties in scleroderma models.
  • Clinical efficacy of imatinib for systemic sclerosis requires further investigation.
  • Targeting TGF-β and PDGF pathways with imatinib has not yet yielded significant clinical benefits in systemic sclerosis.
Keywords:
SScimatinibsclerodermasystemic sclerosistyrosine kinase inhibitor

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
655
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
717